The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy

Thomas J. Guzzo, Brian K. McNeil, Trinity J. Bivalacqua, Debra J. Elliott, Lori J. Sokoll, Mark P. Schoenberg

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Objective: Due to imprecise clinical staging, the finding of extravesical and node-positive disease at the time of radical cystectomy (RC) for patients with clinically localized bladder cancer is not uncommon. Circulating tumor cells (CTCs) have been shown to be present in the peripheral blood of patients with metastatic urothelial carcinoma. The object of this study was to evaluate the ability of CTCs to predict extravesical disease in bladder cancer patients prior to RC. Materials and methods: Peripheral blood samples from 43 patients with bladder cancer were evaluated using the CellSearch (Veridex, LLC, Raritan, NJ) CTC assay prior to RC. The sensitivity, specificity, and positive predictive value (PPV) of CTC status in predicting extravesical disease was calculated. Receiver operating characteristic (ROC) curves were generated to quantify the ability of CTCs to predict extravesical and node-positive disease. Results: CTCs were detected in 9 (21%) patients prior to RC. The sensitivity, specificity, and PPV of CTC status in predicting extravesical disease were 27%, 88% and 78%, respectively. The accuracy of CTC status in predicting extravesical (≥pT3 or node-positive) disease for the entire cohort was 0.576. In a model incorporating preoperative hydronephrosis, CTC status did not improve the predictive accuracy for extravesical disease (0.576 vs. 0.585, P = 0.915). Conclusion: CTCs were detected in low numbers in a small percentage (21%) of patients prior to undergoing RC at our institution. CTC status was not a robust predictor of extravesical or node-positive disease in this cohort. CTC status is not likely to be a clinically useful parameter for directing therapeutic decisions in patients with ≤cT2 bladder cancer.

Original languageEnglish (US)
Pages (from-to)44-48
Number of pages5
JournalUrologic Oncology: Seminars and Original Investigations
Volume30
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Circulating Neoplastic Cells
Cystectomy
Urinary Bladder Neoplasms
Sensitivity and Specificity
Hydronephrosis
ROC Curve

Keywords

  • Bladder cancer
  • Circulating tumor cells
  • Staging

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy. / Guzzo, Thomas J.; McNeil, Brian K.; Bivalacqua, Trinity J.; Elliott, Debra J.; Sokoll, Lori J.; Schoenberg, Mark P.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 30, No. 1, 01.2012, p. 44-48.

Research output: Contribution to journalArticle

Guzzo, Thomas J. ; McNeil, Brian K. ; Bivalacqua, Trinity J. ; Elliott, Debra J. ; Sokoll, Lori J. ; Schoenberg, Mark P. / The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy. In: Urologic Oncology: Seminars and Original Investigations. 2012 ; Vol. 30, No. 1. pp. 44-48.
@article{c59eeb31e18f4d9c824dffe0443c06a6,
title = "The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy",
abstract = "Objective: Due to imprecise clinical staging, the finding of extravesical and node-positive disease at the time of radical cystectomy (RC) for patients with clinically localized bladder cancer is not uncommon. Circulating tumor cells (CTCs) have been shown to be present in the peripheral blood of patients with metastatic urothelial carcinoma. The object of this study was to evaluate the ability of CTCs to predict extravesical disease in bladder cancer patients prior to RC. Materials and methods: Peripheral blood samples from 43 patients with bladder cancer were evaluated using the CellSearch (Veridex, LLC, Raritan, NJ) CTC assay prior to RC. The sensitivity, specificity, and positive predictive value (PPV) of CTC status in predicting extravesical disease was calculated. Receiver operating characteristic (ROC) curves were generated to quantify the ability of CTCs to predict extravesical and node-positive disease. Results: CTCs were detected in 9 (21{\%}) patients prior to RC. The sensitivity, specificity, and PPV of CTC status in predicting extravesical disease were 27{\%}, 88{\%} and 78{\%}, respectively. The accuracy of CTC status in predicting extravesical (≥pT3 or node-positive) disease for the entire cohort was 0.576. In a model incorporating preoperative hydronephrosis, CTC status did not improve the predictive accuracy for extravesical disease (0.576 vs. 0.585, P = 0.915). Conclusion: CTCs were detected in low numbers in a small percentage (21{\%}) of patients prior to undergoing RC at our institution. CTC status was not a robust predictor of extravesical or node-positive disease in this cohort. CTC status is not likely to be a clinically useful parameter for directing therapeutic decisions in patients with ≤cT2 bladder cancer.",
keywords = "Bladder cancer, Circulating tumor cells, Staging",
author = "Guzzo, {Thomas J.} and McNeil, {Brian K.} and Bivalacqua, {Trinity J.} and Elliott, {Debra J.} and Sokoll, {Lori J.} and Schoenberg, {Mark P.}",
year = "2012",
month = "1",
doi = "10.1016/j.urolonc.2009.10.008",
language = "English (US)",
volume = "30",
pages = "44--48",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy

AU - Guzzo, Thomas J.

AU - McNeil, Brian K.

AU - Bivalacqua, Trinity J.

AU - Elliott, Debra J.

AU - Sokoll, Lori J.

AU - Schoenberg, Mark P.

PY - 2012/1

Y1 - 2012/1

N2 - Objective: Due to imprecise clinical staging, the finding of extravesical and node-positive disease at the time of radical cystectomy (RC) for patients with clinically localized bladder cancer is not uncommon. Circulating tumor cells (CTCs) have been shown to be present in the peripheral blood of patients with metastatic urothelial carcinoma. The object of this study was to evaluate the ability of CTCs to predict extravesical disease in bladder cancer patients prior to RC. Materials and methods: Peripheral blood samples from 43 patients with bladder cancer were evaluated using the CellSearch (Veridex, LLC, Raritan, NJ) CTC assay prior to RC. The sensitivity, specificity, and positive predictive value (PPV) of CTC status in predicting extravesical disease was calculated. Receiver operating characteristic (ROC) curves were generated to quantify the ability of CTCs to predict extravesical and node-positive disease. Results: CTCs were detected in 9 (21%) patients prior to RC. The sensitivity, specificity, and PPV of CTC status in predicting extravesical disease were 27%, 88% and 78%, respectively. The accuracy of CTC status in predicting extravesical (≥pT3 or node-positive) disease for the entire cohort was 0.576. In a model incorporating preoperative hydronephrosis, CTC status did not improve the predictive accuracy for extravesical disease (0.576 vs. 0.585, P = 0.915). Conclusion: CTCs were detected in low numbers in a small percentage (21%) of patients prior to undergoing RC at our institution. CTC status was not a robust predictor of extravesical or node-positive disease in this cohort. CTC status is not likely to be a clinically useful parameter for directing therapeutic decisions in patients with ≤cT2 bladder cancer.

AB - Objective: Due to imprecise clinical staging, the finding of extravesical and node-positive disease at the time of radical cystectomy (RC) for patients with clinically localized bladder cancer is not uncommon. Circulating tumor cells (CTCs) have been shown to be present in the peripheral blood of patients with metastatic urothelial carcinoma. The object of this study was to evaluate the ability of CTCs to predict extravesical disease in bladder cancer patients prior to RC. Materials and methods: Peripheral blood samples from 43 patients with bladder cancer were evaluated using the CellSearch (Veridex, LLC, Raritan, NJ) CTC assay prior to RC. The sensitivity, specificity, and positive predictive value (PPV) of CTC status in predicting extravesical disease was calculated. Receiver operating characteristic (ROC) curves were generated to quantify the ability of CTCs to predict extravesical and node-positive disease. Results: CTCs were detected in 9 (21%) patients prior to RC. The sensitivity, specificity, and PPV of CTC status in predicting extravesical disease were 27%, 88% and 78%, respectively. The accuracy of CTC status in predicting extravesical (≥pT3 or node-positive) disease for the entire cohort was 0.576. In a model incorporating preoperative hydronephrosis, CTC status did not improve the predictive accuracy for extravesical disease (0.576 vs. 0.585, P = 0.915). Conclusion: CTCs were detected in low numbers in a small percentage (21%) of patients prior to undergoing RC at our institution. CTC status was not a robust predictor of extravesical or node-positive disease in this cohort. CTC status is not likely to be a clinically useful parameter for directing therapeutic decisions in patients with ≤cT2 bladder cancer.

KW - Bladder cancer

KW - Circulating tumor cells

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=84855642295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855642295&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2009.10.008

DO - 10.1016/j.urolonc.2009.10.008

M3 - Article

C2 - 20005748

AN - SCOPUS:84855642295

VL - 30

SP - 44

EP - 48

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 1

ER -